Advances in the study of posttranslational modifications of histones in head and neck squamous cell carcinoma

被引:0
|
作者
Xiao, Yuyang [1 ,5 ]
Zhang, Yikai [1 ,5 ]
Hu, Yuyang [1 ,5 ]
Zhang, Xupeng [1 ,5 ]
Tan, Jiaqi [2 ]
Yao, Shanhu [3 ,4 ]
Wang, Xingwei [2 ]
Qin, Yuexiang [1 ,2 ]
机构
[1] Cent South Univ, Dept Hlth Management Med, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Otolaryngol Head & Neck Surg, Changsha 410008, Hunan, Peoples R China
[3] Cent South Univ, Xiangya Hosp 3, Dept Radiol, Changsha 410013, Hunan, Peoples R China
[4] Cent South Univ, Key Lab Med Informat Res, Changsha 410013, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Sch Med, Changsha 410013, Hunan, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Head and neck squamous cell carcinoma; Epigenetics; Histone posttranslational modifications; Histone inhibitors; PHASE-II TRIAL; EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION; METHYLTRANSFERASE G9A; STRUCTURAL INSIGHTS; METASTATIC HEAD; INHIBITOR; CANCER; METHYLATION; APOPTOSIS;
D O I
10.1186/s13148-024-01785-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pathogenesis of head and neck squamous cell carcinoma (HNSCC) is notably complex. Early symptoms are often subtle, and effective early screening methods are currently lacking. The tumors associated with HNSCC develop rapidly, exhibit high aggressiveness, and respond poorly to existing treatments, leading to low survival rates and poor prognosis. Numerous studies have demonstrated that histone posttranslational modifications (HPTMs), including acetylation, methylation, phosphorylation, and ubiquitination, play a critical role in the occurrence and progression of HNSCC. Moreover, targeting histone posttranslationally modified molecules with specific drugs has shown potential in enhancing therapeutic outcomes and improving prognosis, underscoring their significant clinical value. This review aims to summarize the role of histone posttranslational modifications in the pathogenesis and progression of HNSCC and to discuss their clinical significance, thereby providing insights into novel therapeutic approaches and drug development for this malignancy.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Basaloid squamous cell carcinoma of the head and neck
    Paulino, AFG
    Singh, B
    Shah, JP
    Huvos, AG
    LARYNGOSCOPE, 2000, 110 (09): : 1479 - 1482
  • [42] Cutaneous squamous cell carcinoma of the head and neck
    Deutsch, Jochen
    Dippel, Edgar
    Delank, K. -Wolfgang
    LARYNGO-RHINO-OTOLOGIE, 2023, 102 (03) : 186 - 193
  • [43] Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Jessica Moskovitz
    Jennifer Moy
    Robert L. Ferris
    Current Oncology Reports, 2018, 20
  • [44] Nivolumab in squamous cell carcinoma of the head and neck
    Specenier, Pol
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (05) : 409 - 420
  • [45] Pharmacotherapy of head and neck squamous cell carcinoma
    Pan, Quintin
    Gorin, Michael A.
    Teknos, Theodoros N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (14) : 2291 - 2302
  • [46] Immunotherapy for Head and Neck Squamous Cell Carcinoma
    Schoppy, David W.
    Sunwoo, John B.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (06) : 1033 - +
  • [47] Chemoprevention of squamous cell carcinoma of the head and neck
    Wrangle, John M.
    Khuri, Fadlo R.
    CURRENT OPINION IN ONCOLOGY, 2007, 19 (03) : 180 - 187
  • [48] Editorial: Advances in the Involvement of Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma
    Lechien, Jerome R.
    Mouawad, Francois
    Hans, Stephane
    Saussez, Sven
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects
    Khadela, Avinash
    Shah, Yesha
    Mistry, Priya
    Bodiwala, Kunjan
    Avinash, C. B.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [50] Advances in tumor immune microenvironment of head and neck squamous cell carcinoma: A review of literature
    Hong, Qichao
    Ding, Shun
    Xing, Chengliang
    Mu, Zhonglin
    MEDICINE, 2024, 103 (09) : E37387